Ribometrix is a technology company.
Ribometrix has raised $38.0M across 2 funding rounds.
Ribometrix has raised $38.0M in total across 2 funding rounds.
Ribometrix has raised $38.0M in total across 2 funding rounds.
Ribometrix's investors include AbbVie Ventures, Hatteras Venture Partners, Hakan Goker, M Ventures (Merck).
Ribometrix is a biotechnology therapeutics company developing small-molecule drugs that target RNA structures to treat human diseases by preventing production of disease-causing proteins.[1][2][3] It serves the healthcare industry, focusing on areas like oncology and other RNA-mediated conditions, solving the challenge of "undruggable" proteins that traditional therapies cannot address by directly modulating RNA biology.[1][2] The company has demonstrated growth momentum through platform maturation, a first-in-field breakthrough in identifying an mRNA-binding small molecule that reduces protein expression, a pipeline of wholly owned programs, and backing from investors like Vertex Pharmaceuticals and Genentech.[1]
Founded in 2014 and based in Durham, North Carolina, Ribometrix has bridged early-stage funding gaps via grants like SBIR/STTR and state programs, enabling infrastructure buildout and pipeline advancement.[1][2]
Ribometrix emerged from UNC-Chapel Hill's incubation ecosystem in 2014, pioneering a novel approach to drug discovery by targeting functional 3D RNA structures rather than proteins, which dominate most therapies.[2] Co-founder Dr. Matthew Warner led the development of its proprietary RNA-targeting small-molecule platform, drawing on advanced technologies to bind RNA and modulate disease pathways.[1][2] Early traction came from competitive federal grants (Phase I SBIR/STTR) and North Carolina's One North Carolina Small Business program, which provided critical "Valley of Death" bridging support, direct feedback, and resources to attract venture capital.[2] A pivotal leadership shift saw Dr. John Marshall succeed Dr. Michael Solomon as CEO, aligning with pipeline expansion efforts.[1]
Ribometrix rides the wave of RNA therapeutics innovation, expanding beyond mRNA vaccines into small-molecule RNA modulation—a trend gaining traction as limitations of protein-targeting drugs become evident for complex diseases.[1][3] Timing aligns with matured screening technologies and post-COVID RNA awareness, amplified by market forces like rising demand for oral therapies and partnerships with big pharma seeking novel modalities.[1] By validating RNA as a druggable target, Ribometrix influences the biotech ecosystem, potentially unlocking treatments for millions with devastating diseases and inspiring platform plays in oncology and beyond.[2]
Ribometrix is poised for pipeline acceleration through partnerships and financing to advance its lead program and expand RNA-degrading capabilities into clinical stages.[1] Trends like AI-driven drug discovery and precision medicine will shape its path, enhancing platform efficiency amid a shift toward RNA-focused portfolios by major players. Its influence may evolve from pioneer to category leader, delivering first-in-class oral drugs that redefine "undruggable" targets—echoing its high-level mission to revolutionize disease treatment via RNA biology.[1][2]
Ribometrix has raised $38.0M across 2 funding rounds. Most recently, it raised $30.0M Series A in November 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2018 | $30.0M Series A | AbbVie Ventures, Hatteras Venture Partners, Hakan Goker, M Ventures (Merck) | |
| Oct 1, 2017 | $8.0M Seed | AbbVie Ventures, Hatteras Venture Partners, Hakan Goker |